Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches - Yahoo Finance
3/23/2022 12:00:00 AM3 years 1 month ago
by Business Wire
by Business Wire
CAMBRIDGE, Mass., March 23, 2022--Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches
- Vaxxas to complete Phase 1 clinical studies in 2022 with the worlds first needle-free COVID-19 vaccine (HexaPro) to be delivered using Companys proprietary microarray patch (HD-MAP) technolog… [+7213 chars] full article...